The University of Oxford has launched the first human trial of a vaccine candidate against the Bundibugyo strain of the Ebola virus, as efforts intensify to contain the ongoing outbreak.
The Phase I study, designated BD-Ebov, will assess the safety and immune response of the ChAdOx1 BDBV vaccine in 50 healthy adults aged 18 to 55 in Oxford. Recruitment is underway, with vaccinations expected to begin following regulatory approval.
The vaccine was developed by the University’s Oxford Vaccine Group and Pandemic Sciences Institute, using the same ChAdOx1 viral vector platform as the Oxford/AstraZeneca COVID-19 vaccine.
To support the trial, the Serum Institute of India (SII) manufactured and stockpiled approximately 620,000 doses of the vaccine candidate within two weeks and supplied 4,000 investigational doses for the Phase I study.
Trial reflects urgency of outbreak
The programme is funded by the Coalition for Epidemic Preparedness Innovations (CEPI) through an $8.6 million grant to Oxford and SII. Additional clinical studies are also being prepared in Uganda, subject to regulatory approval.
Professor Teresa Lambe, the study’s lead scientific investigator, said the trial reflects the urgency of responding to the Bundibugyo outbreak, noting that the vaccine reached human testing just 57 days after the World Health Organization declared the outbreak a Public Health Emergency of International Concern.
If the vaccine is proven safe and produces a strong immune response, CEPI plans to support larger late-stage trials to gather data for emergency use authorization or full licensure.
Africa CDC Director General Dr Jean Kaseya welcomed the milestone, saying that while early-stage trials will not immediately help communities affected by the outbreak, they are essential to developing vaccines for the current epidemic and future outbreaks.
- The University of Oxford has started the first human trial for a vaccine targeting the Bundibugyo Ebola virus strain amid an ongoing outbreak.
- The Phase I BD-Ebov study will test safety and immune response in 50 healthy adults, with vaccinations starting after regulatory approval.
- The vaccine uses the ChAdOx1 viral vector platform, the same technology behind the Oxford/AstraZeneca COVID-19 vaccine.
- The Serum Institute of India rapidly produced about 620,000 doses, supplying 4,000 for the trial, funded by an $8.6 million CEPI grant.
- If successful, larger trials will follow for emergency use approval, with additional studies planned in Uganda, reflecting a swift response to the outbreak.
🎧 Listen to this article
To support the trial, the Serum Institute of India (SII) manufactured and stockpiled approximately 620,000 doses of the vaccine candidate within two weeks and supplied 4,000 investigational doses for the Phase I study.
Professor Teresa Lambe , the study's lead scientific investigator, said the trial reflects the urgency of responding to the Bundibugyo Health Health
If the vaccine is proven safe and produces a strong immune response, CEPI plans to support larger late-stage trials to gather data for emergency use authorization or full licensure.
Africa CDC Director General Dr Jean Kaseya welcomed the milestone, saying that while early-stage trials will not immediately help communities affected by the outbreak, they are essential to developing vaccines for the current epidemic and future outbreaks.
